TOP TEN perturbations for 1325_at (Homo sapiens)

Organism: Homo sapiens
Gene: 1325_at
Selected probe(set): 227798_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1325_at (227798_at) across 6672 perturbations tested by GENEVESTIGATOR:

precursor-B-ALL study 3 (TEL-AML1) / precursor-B-ALL study 3 (MLL-rearranged)

Relative Expression (log2-ratio):6.358783
Number of Samples:15 / 5
Experimental precursor-B-ALL study 3 (TEL-AML1)
Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(12;21)(p13,q22)/TEL-AML1]. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO).
Control precursor-B-ALL study 3 (MLL-rearranged)
Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(v;11q23)/MLL rearranged]. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO).

precursor-B-ALL study 3 (PAX5-rearranged) / precursor-B-ALL study 3 (TEL-AML1)

Relative Expression (log2-ratio):-5.9767866
Number of Samples:6 / 15
Experimental precursor-B-ALL study 3 (PAX5-rearranged)
Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [dic(9;20)(p11-13;q11) )/PAX5 rearranged]. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO).
Control precursor-B-ALL study 3 (TEL-AML1)
Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(12;21)(p13,q22)/TEL-AML1]. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO).

precursor-B-ALL study 7 (PDX; long-term; >10wk) / precursor-B-ALL study 7 (PDX; short-term; <10wk)

Relative Expression (log2-ratio):5.2079744
Number of Samples:7 / 5
Experimental precursor-B-ALL study 7 (PDX; long-term; >10wk)
Leukemia cell samples isolated from spleen of patient derived xenografts (PDX) of precursor B-cell acute lymphoblastic leukemia generated in NOD/SCID mice with time to manifestation of leukemia (TTL) more than 10 weeks (long-term). Cell suspensions containing more than 90% leukemia cells as estimated by flow cytometry were prepared from infiltrated spleens of leukemia bearing mice. Briefly, unconditioned NOD/SCID (NOD.CB17-Prkdcscid/NCrCrl) mice with a median age of 10 weeks were transplanted by injection of patient leukemia cells, which were isolated from bone marrow or peripheral blood of pediatric patients with precursor BCP-ALL, into the lateral tail vein. Upon clear evidence for leukemia related morbidity, mice were killed and autopsy was performed. Leukemia was confirmed detecting leukemia cells in bone marrow, spleen and peripheral blood. Time to leukemia (TTL) was determined as weeks from transplant to clinical leukemia manifestation. Donor characteristics: 3 females and 9 males; 1-9 years old; good response to prednison; no fusion gene; remision at day 33; non-high risk group; late relapse group (relapse after 24 months from diagnosis).
Control precursor-B-ALL study 7 (PDX; short-term; <10wk)
Leukemia cell samples isolated from spleen of patient derived xenografts (PDX) of precursor B-cell acute lymphoblastic leukemia (B-ALL) generated in NOD/SCID mice with time to manifestation of leukemia (TTL) less than 10 weeks (short-term). Cell suspensions containing more than 90% leukemia cells as estimated by flow cytometry were prepared from infiltrated spleens of leukemia bearing mice. Briefly, unconditioned NOD/SCID (NOD.CB17-Prkdcscid/NCrCrl) mice with a median age of 10 weeks were transplanted by injection of patient leukemia cells, which were isolated from bone marrow or peripheral blood of pediatric patients with BCP-ALL, into the lateral tail vein. Upon clear evidence for leukemia related morbidity, mice were killed and autopsy was performed. Leukemia was confirmed detecting leukemia cells in bone marrow, spleen and peripheral blood. Time to leukemia (TTL) was determined as weeks from transplant to clinical leukemia manifestation. Donor characteristics: 3 females and 9 males; 1-9 years old; good response to prednison; no fusion gene,;remision at day 33; non-high risk group; early relapse group (relapse within 24 months from diagnosis).

precursor-B-ALL study 1 (t(12;21)(p12,q22)) / normal bone marrow sample

Relative Expression (log2-ratio):5.011179
Number of Samples:58 / 74
Experimental precursor-B-ALL study 1 (t(12;21)(p12,q22))
Bone marrow samples of patients with precursor B-ALL (t(12;21)(p12,q22)/TEL-AML1).
Control normal bone marrow sample
Non-leukemic and healthy bone marrow sample.

precursor-B-ALL study 2 (MLL-rearranged) / precursor-B-ALL study 2 (TEL-AML1)

Relative Expression (log2-ratio):-4.950321
Number of Samples:4 / 21
Experimental precursor-B-ALL study 2 (MLL-rearranged)
Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(v;11q23)/MLL rearranged]. Patients were part of the Dutch Childhood Oncology Group (DCOG).
Control precursor-B-ALL study 2 (TEL-AML1)
Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(12;21)(p13,q22)/TEL-AML1]. Patients were part of the Dutch Childhood Oncology Group (DCOG).

precursor-B-ALL study 3 (hyperdiploid) / precursor-B-ALL study 3 (MLL-rearranged)

Relative Expression (log2-ratio):4.623291
Number of Samples:17 / 5
Experimental precursor-B-ALL study 3 (hyperdiploid)
Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL (hyperdiploidy). Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO).
Control precursor-B-ALL study 3 (MLL-rearranged)
Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(v;11q23)/MLL rearranged]. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO).

precursor-B-ALL study 3 (MLL-rearranged) / precursor-B-ALL study 3 (BCR-ABL)

Relative Expression (log2-ratio):-4.603794
Number of Samples:5 / 4
Experimental precursor-B-ALL study 3 (MLL-rearranged)
Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(v;11q23)/MLL rearranged]. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO).
Control precursor-B-ALL study 3 (BCR-ABL)
Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(9;22)(q34;q11.2)/BCR-ABL1]. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO).

lung cancer study 1 (PDX; pseudosarcomatous carcinoma; primary) / lung cancer study 1 (PDX; non-small cell carcinoma; primary)

Relative Expression (log2-ratio):4.45487
Number of Samples:4 / 2
Experimental lung cancer study 1 (PDX; pseudosarcomatous carcinoma; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary pseudosarcomatous carcinoma of the lung (subcutaneously implanted).
Control lung cancer study 1 (PDX; non-small cell carcinoma; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary non-small cell carcinoma of the lung (subcutaneously implanted).

dendritic cell study 6 (gardiquimod; RN486) / dendritic cell study 6 (CpG A; RN486)

Relative Expression (log2-ratio):4.404223
Number of Samples:4 / 4
Experimental dendritic cell study 6 (gardiquimod; RN486)
Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors and treated with gardiquimod (TLR7 agonist) and RN486 (Bruton’s tyrosine kinase; BTK inhibitor) for 3 hours. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+.
Control dendritic cell study 6 (CpG A; RN486)
Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors and treated with CpG-A ODN2216 Class A (TLR9 agonist) and RN486 (Bruton’s tyrosine kinase; BTK inhibitor) for 3 hours. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+.

Langerhans cell histiocytosis study 4 / normal tonsillar T-lymphocyte sample

Relative Expression (log2-ratio):-4.2705803
Number of Samples:7 / 4
Experimental Langerhans cell histiocytosis study 4
CD3+ T-lymphocyte samples isolated from peripheral blood of patients with Langerhans cell histiocytosis, prior to chemotherapy treatment. Patient with different clinical status were included in this study (unifocal, single system and multifocal, single system disease).
Control normal tonsillar T-lymphocyte sample
Normal tonsillar CD3+ T-lymphocytes were isolated from children who undergone elective tonsillectomy. The T-cells were isolated from presumably healthy tissue.